Core Viewpoint - The innovative medical device market is witnessing a surge in IPO activities across various segments, indicating a shift towards capitalization and maturity in the industry [1][20]. Group 1: IPO Developments - Several innovative medical device companies are moving towards IPO, including Saiwei Technology in the ophthalmic OCT field, Qiangnao Technology in brain-computer interfaces, and Pusong Medical in single-use endoscopes [1][19]. - The emergence of these IPOs suggests that multiple niche markets are collectively advancing, marking a new phase of high-end and capitalized development for domestic innovative medical devices [20]. Group 2: Investment Trends - Since 2020, there has been a significant influx of investment in the innovative medical device sector, with the number of financing events increasing from 118 in 2019 to 475 in 2021, although it has slightly decreased in subsequent years [5][21]. - The single-use endoscope sector has seen substantial funding, with companies like Ruipai Medical completing multiple rounds of financing, contributing to rapid industry growth [23]. Group 3: Policy and Market Support - Recent government policies have been implemented to support the high-quality development of innovative medical devices, facilitating their commercialization and market entry [8][24]. - For instance, the inclusion of artificial heart surgeries in insurance coverage has reduced patient financial burdens, leading to increased market growth for related companies [9][25]. Group 4: Future Outlook - The upcoming years are expected to see more niche markets achieving their first IPOs, particularly in areas like oral and hair transplant surgical robots, which have demonstrated commercial viability [30][31]. - The successful IPOs of these companies are anticipated to further accelerate industry growth and market penetration, fostering a more mature market landscape [32].